Giordano Christopher Thomas's Form 4 filing
Tenax Therapeutics, Inc. (TENX) · filed Sep 15, 2026
- Accession no.
- 0001871714-26-000002
- Filed
- Sep 15, 2026, 9:38 PM ET
- Trade date
- Sep 11-15, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $20.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Giordano Christopher ThomasCIK 0001871714 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | PPurchaseAcquired | +6,000 | $1.88 | +$11,250 | 17,324 | Direct | |
| Sep 15, 2026 | Common Stock | PPurchaseAcquired | +4,850 | $1.82 | +$8,837.19 | 22,174 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.